<DOC>
	<DOC>NCT01713283</DOC>
	<brief_summary>This study is to evaluate the safety, tolerability, and antiviral activity of sofosbuvir (SOF) with ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>First generation Egyptian; must have been born in Egypt and can trace both maternal and paternal Egyptian ancestry Treatmentexperienced or treatmentnaive Chronic genotype 4 HCV infection Not coinfected with HIV Screening laboratory values within defined thresholds Use of highly effective contraception methods Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments History of any other clinically significant chronic liver disease Pregnant or nursing female or male with pregnant female partner History of clinicallysignificant illness or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol Excessive alcohol ingestion or significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>